Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Eli Lilly is leading with a phase II trial initiated in early 2025 to evaluate mazdutide, a GLP-1/GIP dual agonist, in participants with AUD
Avoid these combinations
Lilly has submitted orforglipron to regulators in over 40 countries, with submission for type 2 diabetes in the U.S
Patients without significant cardiovascular disease who prioritize efficacy over regulatory approval status fit the Retatrutide profile well
US$ 22.72
US$ 27.14
US$ 22.58
US$ 20.63
